Tumors in <i>MLH1</i> and <i>MSH2</i> variant carriers often display MMR deficiency (dMMR) and/or high microsatellite instability (MSI-H), two predictive biomarkers for immunotherapy efficacy. This evidence concerns the gene MSH2 and mismatch repair cancer syndrome 1.